Literature DB >> 26617716

Inhibition of SALL4 suppresses carcinogenesis of colorectal cancer via regulating Gli1 expression.

Ji Cheng1, Rui Deng1, Chuanqing Wu1, Peng Zhang1, Ke Wu1, Liang Shi1, Xinghua Liu1, Jie Bai1, Meizhou Deng1, Jinbo Gao1, Xiaoming Shuai1, Guobin Wang1, Kaixiong Tao1.   

Abstract

BACKGROUND: SALL4 is a novel oncogene mediating tumorigenesis in multiple carcinomas. However, its actual role and mechanisms participating in the development of colorectal cancer remains unclear.
METHODS: Immunohistochemical staining and Western blot were conducted to detect the expression of SALL4 and other molecules. siRNA of SALL4 was transfected to silence SALL4 expression in Caco-2 cell line. Flow cytometry was used for cell cycle and apoptosis analysis. Wound healing and transwell assay were used for invasion test. CCK-8 test was employed for cell proliferation and drug sensitivity assessment.
RESULTS: By inhibition of SALL4 expression, the proliferation, invasiveness and drug resistance were dramatically reduced while apoptosis rate was up-regulated. Gli1 was found to decrease its expression in SALL4 silencing cells. Moreover, the inhibition on tumorigenesis of Caco-2 by SALL4 silencing was antagonized by Gli1 up-regulation, suggesting Gli1 as a downstream target of SALL4 in cancer development.
CONCLUSION: SALL4 inhibition limited oncogenesis on colorectal cancer by reducing Gli1 expression.

Entities:  

Keywords:  Gli1; SALL4; carcinogenesis; colorectal cancer

Mesh:

Substances:

Year:  2015        PMID: 26617716      PMCID: PMC4637531     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

Review 1.  Hedgehog signalling in gut development, physiology and cancer.

Authors:  Juanita L Merchant
Journal:  J Physiol       Date:  2011-12-05       Impact factor: 5.182

2.  SALL4, a novel marker for human gastric carcinogenesis and metastasis.

Authors:  L Zhang; Z Xu; X Xu; B Zhang; H Wu; M Wang; X Zhang; T Yang; J Cai; Y Yan; F Mao; W Zhu; Q Shao; H Qian; W Xu
Journal:  Oncogene       Date:  2013-11-25       Impact factor: 9.867

Review 3.  Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.

Authors:  P Ramos; M Bentires-Alj
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

4.  Adjuvant bevacizumab in colon cancer: where did we go wrong?

Authors:  Matthew T Seymour
Journal:  Lancet Oncol       Date:  2012-11-16       Impact factor: 41.316

5.  Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.

Authors:  Kjell Magne Tveit; Tormod Guren; Bengt Glimelius; Per Pfeiffer; Halfdan Sorbye; Seppo Pyrhonen; Fridbjorn Sigurdsson; Elin Kure; Tone Ikdahl; Eva Skovlund; Tone Fokstuen; Flemming Hansen; Eva Hofsli; Elke Birkemeyer; Anders Johnsson; Hans Starkhammar; Mette Karen Yilmaz; Nina Keldsen; Anne Berit Erdal; Olav Dajani; Olav Dahl; Thoralf Christoffersen
Journal:  J Clin Oncol       Date:  2012-04-02       Impact factor: 44.544

Review 6.  Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update.

Authors:  Naoko Takebe; Lucio Miele; Pamela Jo Harris; Woondong Jeong; Hideaki Bando; Michael Kahn; Sherry X Yang; S Percy Ivy
Journal:  Nat Rev Clin Oncol       Date:  2015-04-07       Impact factor: 66.675

Review 7.  SALL4: an emerging cancer biomarker and target.

Authors:  Xu Zhang; Xiao Yuan; Wei Zhu; Hui Qian; Wenrong Xu
Journal:  Cancer Lett       Date:  2014-11-20       Impact factor: 8.679

8.  SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice.

Authors:  Yupo Ma; Wei Cui; Jianchang Yang; Jun Qu; Chunhui Di; Hesham M Amin; Raymond Lai; Jerome Ritz; Diane S Krause; Li Chai
Journal:  Blood       Date:  2006-06-08       Impact factor: 22.113

Review 9.  Monoclonal antibodies in lung cancer.

Authors:  Yujiong Wang; Guangcun Deng; Xiaoming Liu; William C Cho
Journal:  Expert Opin Biol Ther       Date:  2012-12-14       Impact factor: 4.388

Review 10.  Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes.

Authors:  Janneke F Linnekamp; Xin Wang; Jan Paul Medema; Louis Vermeulen
Journal:  Cancer Res       Date:  2015-01-15       Impact factor: 12.701

View more
  9 in total

Review 1.  Functional analysis of Cullin 3 E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Zhiwei Wang; Brian J North; Kaixiong Tao; Xiangpeng Dai; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-11-08       Impact factor: 10.680

2.  SALL4 promotes gastric cancer progression through activating CD44 expression.

Authors:  X Yuan; X Zhang; W Zhang; W Liang; P Zhang; H Shi; B Zhang; M Shao; Y Yan; H Qian; W Xu
Journal:  Oncogenesis       Date:  2016-11-07       Impact factor: 7.485

3.  SALL4 induces radioresistance in nasopharyngeal carcinoma via the ATM/Chk2/p53 pathway.

Authors:  Xin Nie; Ergang Guo; Cheng Wu; Dongbo Liu; Wei Sun; Linli Zhang; Guoxian Long; Qi Mei; Kongming Wu; Huihua Xiong; Guoqing Hu
Journal:  Cancer Med       Date:  2019-03-24       Impact factor: 4.452

4.  Knockdown of SALL4 Inhibits Proliferation, Migration, and Invasion in Osteosarcoma Cells.

Authors:  Dengfeng Zhang; Feng Jiang; Xiao Wang; Guojun Li
Journal:  Oncol Res       Date:  2016-10-27       Impact factor: 5.574

Review 5.  SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance.

Authors:  Boshu Sun; Liangliang Xu; Wenhui Bi; Wen-Bin Ou
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

Review 6.  SALL4: An Intriguing Therapeutic Target in Cancer Treatment.

Authors:  Shiva Moein; Daniel G Tenen; Giovanni Amabile; Li Chai
Journal:  Cells       Date:  2022-08-20       Impact factor: 7.666

7.  Dysregulated Expression of Three Genes in Colorectal Cancer Stratifies Patients into Three Risk Groups.

Authors:  Alba Rodriguez; Luís Antonio Corchete; José Antonio Alcazar; Juan Carlos Montero; Marta Rodriguez; Luis Miguel Chinchilla-Tábora; Rosario Vidal Tocino; Carlos Moyano; Saray Muñoz-Bravo; José María Sayagués; Mar Abad
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

8.  SALL4 activates TGF-β/SMAD signaling pathway to induce EMT and promote gastric cancer metastasis.

Authors:  Xu Zhang; Peng Zhang; Meng Shao; Xueyan Zang; Jiayin Zhang; Fei Mao; Hui Qian; Wenrong Xu
Journal:  Cancer Manag Res       Date:  2018-10-10       Impact factor: 3.989

Review 9.  SALL Proteins; Common and Antagonistic Roles in Cancer.

Authors:  Claudia Álvarez; Aracelly Quiroz; Diego Benítez-Riquelme; Elizabeth Riffo; Ariel F Castro; Roxana Pincheira
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.